Inhibition of 11β-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice
The 11β-hydroxysteroid dehydrogenase type-1 inhibitor BVT.2733 lowers blood glucose and insulin in mutant mouse models of obesity and diabetes. Its effects on energy balance and body composition, and their contribution to improved glucose homeostasis have received little attention.
Materials and methods
BVT.2733 (100 mg/kg, orally) was given twice daily to lean and diet-induced obese mice for 16 or 17 days. A group of obese mice was pair-fed to the amounts consumed by BVT.2733-treated mice.
In both obese and lean mice, BVT.2733 reduced food intake and weight gain, but increased water intake. Pair-feeding caused almost as great a decrease in body weight as BVT.2733. Energy expenditure was 38±8% higher in the BVT.2733-treated obese mice than in the pair-fed mice. Terminal plasma corticosterone was raised, lean body weight reduced and percentage fat unchanged in the pair-fed mice (control, 47.8±2.6%; pair-fed, 47.1±1.9%), whereas BVT.2733 did not reduce lean mass, but did reduce percentage fat (40.9±2.0%). BVT.2733 but not pair-feeding reduced both the glucose tolerance AUC and the plasma insulin concentration 30 min after giving glucose.
BVT.2733 reduced food intake but prevented a concomitant reduction in lean body mass and energy expenditure. The latter effects may have contributed to improved glucose tolerance.
- Alberts P, Engblom L, Edling N et al (2002) Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45:1528–1532 CrossRef
- Alberts P, Nilsson C, Selen G et al (2003) Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144:4755–4762 CrossRef
- Hermanowski-Vosatka A, Balkovec JM, Cheng K et al (2005) 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202:517–527 CrossRef
- Morton NM, Paterson JM, Masuzaki H et al (2004) Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53:931–938 CrossRef
- Zorrilla EP, Tache Y, Koob GF (2003) Nibbling at CRF receptor control of feeding and gastrocolonic motility. Trends Pharmacol Sci 24:421–427 CrossRef
- Richard D, Huang Q, Timofeeva E (2000) The corticotropin-releasing hormone system in the regulation of energy balance in obesity. Int J Obes Relat Metab Disord 24 [Suppl 2]:S36–S39
- Arch JR (2002) β3-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol 440:99–107 CrossRef
- Hulver MW, Dohm GL (2004) The molecular mechanism linking muscle fat accumulation to insulin resistance. Proc Nutr Soc 63:375–380 CrossRef
- Jobin N, de Jonge L, Garrel DR (1996) Effects of RU 486 on energy expenditure and meal tolerance in normal men. J Am Coll Nutr 15:283–288
- Stewart PM, Krozowski ZS (1999) 11-Hydroxysteroid dehydrogenase. Vitam Horm 57:249–324 CrossRef
- Inhibition of 11β-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice
Volume 49, Issue 6 , pp 1333-1337
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Body composition
- Diet-induced obesity
- Energy expenditure
- Energy intake
- Glucose tolerance
- 11β-Hydroxysteroid dehydrogenase type-1
- Metabolic syndrome
- Industry Sectors
- Author Affiliations
- 1. Clore Laboratory, University of Buckingham, Buckingham, MK18 1EG, UK
- 2. Alderley Park, AstraZeneca, Macclesfield, UK